Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1934-1941

  Roth, Michael D ^a   Gitlitz, Barbara J ^a   Kiertscher, Sylvia M ^a   Park, Alice N ^a   Mendenhall, Marcy ^a   Moldawer, Nancy ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD83 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 4; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD18; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; INTERLEUKIN-4; LYMPHOCYTES; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0034028216     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Grabbe, S., Beissert, S., Schwarz, T., and Granstein, R. D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today, 16: 117-121, 1995.
2. Huang, A., Golumbek, P., Ahmadzadeh, M., Jaffe, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
3. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1297-1302, 1995.
4. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
5. Paglia, P., Chiodon, C., Rodolfo, M., Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
6. Nair, S. K., Snyder, D., Rouse, B. T., and Gilboa, E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer. 70: 706-715, 1997.
7. Ribas, A., Butterfield, L. H., McBride, W. H., Jilani, S. M., Bui, L. A., Vollmer, C. M., Lau, R., Dissette, V. B., Hu, B., Chen, A. Y., and Economou, J. E. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 57: 2865-2869, 1997.
8. Ambe, K., Mori, M., and Enjoji, M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer (Phila.), 63: 496-503, 1989.
9. Furukawa, T., Watanabe, S., Kodama, T., Sato, Y., Shimosato, Y., and Suemasu, K. T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer (Phila.), 56: 2651-2656, 1985.
10. Ishigami, S., Aikou, T., Natsugoe, S., Hokita, S., Iwashige, H., Tokushige, M., and Sonoda, S. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology (Basel), 55: 65-69, 1998.
11. Schroder, S., Schwarz, W., Rehpenning, W., Loning, T., and Bocker, W. Dendritic/ Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am. J. Clin. Pathol., 89: 295-300, 1988.
12. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
13. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
14. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996.
15. Tjoa, B. A., Elgamal, A. A., and Murphy, G. P. Vaccine therapy for prostate cancer. Urol. Clin. North Am., 26: 365-374, 1999.
16. Rosenzwajg, M., Canque, B., and Gluckman, J. C. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood, 87: 535-544, 1996.
17. Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D., and Banchereau, J. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF-α. J. Exp. Med., 184: 695-706, 1996.
18. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
19. Kiertscher, S., and Roth, M. D. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dencritic cells when cultured in GM-CSF and IL-4. J. Leukocyte Biol., 59: 208-218, 1996.
20. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
21. Rosenzwajg, M., Camus, S., Guigon, M., and Gluckman, J. C. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp. Hematol., 26: 63-72, 1998.
22. + dendritic cell precursors in vitro. J. Leukocyte Biol., 64: 235-244, 1998.
23. Zhou, L. J. and Tedder, T. F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA. 93: 2588-2592, 1996.
24. Paquette, R. L., Hsu, N. C., Kiertscher, S. M., Park, A. N., Tran, L., Roth, M. D., and Glaspy J. A. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukocyte Biol., 64: 358-367, 1998.
25. Brossart, P., Grunebach, F., Stuhler, G., Reichardt, V. L., Mohle, R., Kanz, L., and Brugger, W. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood, 92: 4238-4247, 1998.
26. Piemonti, L., Bernasconi, S., Luini, W., Trobonjaca, Z., Minty, A., Allavena, P., and Mantovani, A. IL-13 supports differentiation of dendritic cells from circulating precursors in concert with GM-CSF. Eur. Cytokine Network, 6: 245-252, 1995.
27. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanough, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
28. Sallusto, F., Cella, M., Danielli, C., and Lanzavechecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med., 182: 389-400, 1995.
29. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 258: 1795-1798, 1992.
30. Ochoa, A. C., and Longo, D. L. Alteration of signal transduction in T cells from cancer patients. Important Adv. Oncol., 43-54: 1995.
31. Cella, M., Sallusto, F., and Lanzavecchia, A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol., 9: 10-16, 1997.
32. Hart, D. N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 90: 3245-3287, 1997.
33. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
34. Troy, A. J., Summers, K. L., Davidson, P. J., Atkinson, C. H., and Hart, D. N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res., 4: 585-593, 1998.
35. Enk, A. H., Jonuleit, H., Saloga, J., and Knop, J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer, 73: 309-316, 1997.
36. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
37. Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., and Blay, J. Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 92: 4778-4791, 1998.
38. Allavena, P., Piemonti, L., Longoni, D., Bernasconi, S., Stoppacciaro, A., Ruco, L., and Mantovani, A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol., 28: 359-369, 1998.
39. Morse, M. A., Zhou, L. J., Tedder, T. F., Lyerly, H. K., and Smith, C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte- macrophage colony-stimulating factor, inierleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann. Surg., 226: 6-16, 1997.
40. Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S., Schlom, J., Ryback, M. E., and Lyerly, H. K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res., 5: 1331-1338, 1999.
41. Sharma, S., Miller, P. W., Stolina, M., Zhu, L., Huang, M., Paul, R. W., and Dubinett, S. M. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther., 4: 1361-1370, 1997.
42. Chen, K., Braun, S., Lyman, S., Fan, Y., Traycoff, C. M., Wiebke, E. A., Gaddy, J., Sledge, G., Broxmeyer, H. E., and Cornetta, K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res., 57: 3511-3516, 1997.
43. Lynch, D. H., Andreasen, A., Maraskovsky, E., Whitmore, J., Miller, R. E., and Schuh, J. C. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med., 3: 625-631, 1997.
44. Esche, C., Subbotin, V. M., Maliszewski, C., Lotze, M. T., and Shurin, M. R. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res., 58: 380-383, 1998.
45. Bukowski, R. M., Murthy, S., McLain, D., Finke, J., Anresen, S., Tubbs, R., Bauer, I., Gibson, V., Budd, G. T., and Thomassen, M. J. Phase I trial of recombinant GM-CSF in patients with lung cancer: clinical and immunologic effects. J. Immunother., 13: 267-274, 1993.
46. Phillips, N., Jacobs, S., Stoller, R., Earle, M., Przepiorka, D., and Shadduck, R. K. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in patients with refractory metastatic carcinoma. Blood, 74: 26-34, 1989.
47. Gilleece, M. H., Scarffe, J. H., Ghosh, A., Heyworth, C. M., Bonnem, E., Testa, N., Stern, P., and Dexter, T. M. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections: a Phase I dose toxicity trial. Br. J. Cancer, 66: 204-210, 1992.
48. Ghosh, A. K., Smith, N. K., Prendiville, J., Thatcher, N., Crowther, D., and Stern, P. L. A Phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. Eur. Cytokine Network, 4: 205-211, 1993.
49. Whitehead, R. P., Unger, J. M., Goodwin, J. W., Walker, M. J., Thompson, J. A., Flaherty, L. E., and Sondak, V. K. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J. Immunother., 21: 440-446, 1998.
50. Rini, B. I., Stadler, W. M., Spielberger, R. T., Ratain, M. J., and Vogelzang, N. J. Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: a Phase II trial. Cancer (Phila.), 82: 1352-1358, 1998.
51. O'Doherty, U., Peng, M., Gezelter, S., Swiggard, W. J., Betjes, M., Bhardwaj, N., and Steinman, R. M. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology, 82: 487-493, 1994.
52. O'Doherty, L., Steinman, R. M., Peng, M., Cameron, P. U., Gezelter, S., Kopeloff, I., Swiggard, W. J., Pope, M., and Bhardwaj, N. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J. Exp. Med., 178: 1067-1076, 1993.
53. Small, E. J., Reese, D. M., Um, B., Whisenant, S., Dixon, S. C., and Figg, W. D. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 5: 1738-1744, 1999.
54. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sznol, M., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Seipp, C. A., Einhorn, J. H., Rogers-Freezer, L., and White, D. E. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol., 163: 1690-1695. 1999.
55. Simmons, S. J., Tjoa, B. A., Rogers, M., Elgamal, A., Kenny, G. M., Ragde, H., Troychak, M. J., Boynton, A. L., and Murphy, G. P. GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial. Prostate, 39: 291-297, 1999.